Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D1X2VT
|
|||
| Drug Name |
JNJ-56136379
|
|||
| Synonyms |
JNJ-6379
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Hepatitis B [ICD-11: 1E51; ICD-10: B18.1] | Phase 2 | [1] | |
| Company |
Janssen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hepatitis B virus Capsid protein (HBV C) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03361956) An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection. U.S. National Institutes of Health. | |||
| REF 2 | JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection. Gastroenterology. 2020 Aug;159(2):521-533.e9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.